Siddharth Singh

64PUBLICATIONS
80CO-AUTHORS
Disease surveillanceMedical biotechnology diagnostics (incl. biosensors)Epidemiological modellingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (64)

|Apr 03, 2026
An Enhanced Treatment Algorithm Targeting Mucosal Healing Is Effective and Safe in Older Patients With Crohn's Disease: A Post Hoc Analysis of the REACT2 Trial.

Shane W Goodwin, Sudheer Kumar Vuyyuru, Rocio Sedano

|Jan 07, 2026
Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study.

Siddharth Singh, Brant J Oliver, Jason K Hou

|Oct 29, 2025
Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S. Claims-Based Study.

Dhruv Ahuja, Kuan-Hung Yeh, Sagar B Patel

|Oct 16, 2025
Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases.

Dhruv Ahuja, Soo-Kyung Park, Kuan-Hung Yeh

|Mar 31, 2025
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.

Siddharth Singh, Jasmine D Nguyen, David I Fudman

|Dec 11, 2024
Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.

Austin Haynesworth, Kuan-Hung Yeh, Han Hee Lee

Pageof 11

Frequent Collaborators

17 joint publications

Vipul Jairath

15 joint publications

William Sandborn

15 joint publications

Christopher Ma

14 joint publications

Parambir S Dulai